The NCI PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program that supports the preclinical development of innovative interventions and predictive biomarkers for cancer prevention and interception towards clinical applications in high-risk populations. All interested researchers with innovative ideas in precision cancer prevention are encouraged to apply.

Deadline: Submission deadlines occur twice per year on the second Monday in January and July. The next concept application submission deadline is Monday, July 10, 2023.

 PREVENT’s current research priority areas are:

• Immunoprevention (e.g., vaccines for cancers associated or not associated with infectious agents, immunomodulatory agents, etc.)
• Chemoprevention (e.g., novel mechanisms, anti-inflammatory approaches, drug repurposing, toxicity reduction strategies, etc.)
• Clinically translatable, response-predictive biomarkers (e.g., biomarkers predictive for tumor development and progression, biomarkers useful for monitoring cancer prevention efficacy, etc.)

For more information, a list of current projects, and the application visit the PREVENT web page.

The NCI Division of Cancer Prevention is issuing a call for nominations to feature early career scientists conducting research within the mission of the Division. Individuals selected for this opportunity will be highlighted on the NCI DCP website and in social media led by the Division. Selected individuals will also be considered for opportunities to present their research to an NCI audience. The overall goal of this activity is to increase the visibility of early-career scientists conducting research within the areas supported by DCP, which include:

• cancer early detection biomarker development and screening
• intervention development for cancer prevention
• precision cancer prevention
• symptom science and management

Find more information on the Call for Nominations and Instruction for Nominators on the Early Career Scientist Opportunity webpage.

NCI, the Alliance of Pancreatic Cancer Consortia (ApaCC), and the European Liquid Biopsy Society (ELBS) have organized this workshop on the Role of Extracellular Vesicles (EVs) in Early Detection of Pancreatic Cancer. This virtual workshop, held Thursday, May 25 and Friday, May 26, will focus on the biology of EVs in pancreatic cancer, new technology for isolating and detecting EVs for biomarkers, and the discovery and validation of EVs based biomarkers. Registration is required.

At the request of NCI leadership, we invite you to attend the trans-NCI virtual workshop entitled The Diverse Aspects of Uterine Serous Cancer (USC). The event will be held virtually on Thursday, June 22 and Friday, June 23. The workshop will open with short talks to set the stage and two scientific sessions focused on the basic and translational science related to serous endometrial cancer, followed by a breakout discussion session with the aim of finalizing the identified gaps in the field and potential research opportunities. Registration is required by 5 p.m. ET on June 21, 2023.